ABSTRACT
La infección esofágica por virus del herpes es una entidad rara que se ha reportado con mayor frecuencia en pacientes inmunocomprometidos. Esta infección afecta principalmente a pacientes con virus de la inmunodeficiencia humana (VIH) y a pacientes que reciben terapia inmunosupresora o quimioterapia. La severidad de los síntomas está relacionada con el grado de afectación esofágica, siendo la odinofagia la presentación clínica más frecuente. Por otro lado, el hallazgo endoscópico más común es la presencia de úlceras múltiples bien circunscritas que se presentan típicamente en el tercio distal del esófago. El tratamiento estándar descrito es el aciclovir oral por 1 a 2 semanas.
Esophageal herpes viral infections are rare condition that have been reported most frequently in immunocompromised patients. This infection primarily affects patients with human immunodeficiency virus (HIV) and patients receiving immunosuppressants or chemotherapy. The severity of symptoms is related to the degree of esophageal involvement. Odynophagia is the most common clinical presentation while the most common endoscopic finding is multiple well-circumscribed ulcers. These typically occur in the distal third of the esophagus. Standard treatment is oral acyclovir for one to two weeks.
Subject(s)
Humans , Female , Adult , Esophagitis , Herpesvirus 1, Human , Immunosuppression TherapyABSTRACT
As one of the immediate-early(IE)proteins of herpes simplex virus type 1(HSV-1),ICP22 is a multifunctional viral regulator that localizes in the nucleus of infected cells.It is required in experimental animal systems and some nonhuman cell lines,but not in Vero or HEp-2 cells.ICP22 is extensively phosphorylated by viral and cellular kinases and nucleotidylylated by casein kinase Ⅱ.It has been shown to be required for efficient expression of early(E)genes and a subset of late(L)genes.ICP22,in conjunction with the UL13 kinase,mediates the phosphorylation of RNA polymerase Ⅱ.Both ICP22 and UL13 are required for the activation of ode2,the degradation of cyclins A and B and the acquisition of a new cdc2 partner,the UL42 DNA polymerase processivity factor.The cdc2-UL42 complex mediates postranscriptional modification of topoisomerase Ⅱa in an ICP22-dependent manner to promote L gene expression.In addition,ICP22 interacts with cdk9 in a Us3 kinase dependent fashion to phosphorylate RNA polymerase Ⅱ.